Annovis Bio, Inc. (ANVS) shares surged 17% following the announcement of a new U.S. patent for its lead drug candidate, Buntanetap. This patent expands the drug’s potential applications in preventing and treating neurological injuries linked to brain infections, which can exacerbate neurodegenerative conditions like Alzheimer’s and Parkinson’s diseases. The patent, which extends protection for Buntanetap through 2044, enhances Annovis’ intellectual property portfolio and positions the company favorably in the competitive biotech landscape.

The new patent comes as Annovis progresses through a pivotal Phase 3 trial for early Alzheimer’s patients, with 65% enrollment completed. A recent positive review from the Data Safety Monitoring Board supports the trial’s continuation. Additionally, the company is advancing its Parkinson’s disease initiatives, having received FDA backing for a new dementia study following encouraging cognitive improvement data from previous trials.

For market professionals, the key takeaway is that Annovis’ strengthened patent position and ongoing clinical trials could lead to significant milestones in the neurodegenerative space, potentially driving further stock appreciation as developments unfold.

Source: nasdaq.com